• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CoMentis's Drug Found Safe and Well-Tolerated in Alzheimer's Therapy

Posted on: Tuesday, 8 January 2008, 03:00 CST

CoMentis has completed a Phase I study of its orally bioavailable, small-molecule beta-secretase inhibitor, CTS-21166, which is being developed as a disease-modifying treatment for Alzheimer's disease. Results from the study indicate that CTS-21166 is safe and well-tolerated.

CoMentis said that pharmacodynamic proof of activity was achieved as subjects displayed a robust, sustained and dose-related reduction in plasma amyloid beta in both area-under-curve (AUC) reduction and peak reduction with effects lasting over 72 hours. Single dose administration of CTS-21166 produced a greater than 60% reduction of plasma amyloid beta measured either by AUC over 24 hours or as a maximal reduction relative to predose levels. The top doses of CTS-21166 further demonstrated a sustained reduction in AUC that was greater than 40% over 72 hours.

Henry Hsu, chief medical officer of CoMentis, said: "These data represent a significant advancement in the development of novel therapeutics to treat Alzheimer's disease. CTS-21166 produced a rapid and significant reduction of plasma amyloid beta, a key biomarker that is believed to be involved in the pathogenesis of Alzheimer's disease."

Source: Datamonitor

More News in this Category